Use of riluzole prodrugs to treat alzheimer&#39;s disease

ABSTRACT

Disclosed are methods of treating Alzheimer&#39;s Disease by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No.17/261,057 filed Jan. 18, 2021, which is a national stage applicationunder 35 U.S.C. § 371 of International Application No.PCT/US2019/042718, filed Jul. 20, 2019, which claims priority to U.S.Provisional Application No. 62/701,814 filed Jul. 22, 2018, and all thebenefits accruing therefrom under 35 U.S.C. § 119, the disclosure ofeach of which applications is herein incorporated by reference in itsentirety.

FIELD OF THE INVENTION

The present invention relates to the use of prodrugs of riluzole totreat Alzheimer's disease.

BACKGROUND OF THE INVENTION

Alzheimer's disease is a progressive, fatal neurodegenerative dementia.It accounts for up to 80% of dementias. According to the Alzheimer'sAssociation, in 2016 there were approximately 5.5 million people in theUnited States with the disease, and that number is expected to escalaterapidly in the coming years as the population ages. Reduced glutamateuptake transporters have been reported in postmortem brain tissue ofindividuals with Alzheimer's disease and the level of glutamatetransporter reduction correlates with cognitive impairment as well asmarkers of synaptic density and neurodegeneration.

The emotional and financial burden of AD to patients, family members,and society is enormous, and is predicted to grow exponentially as themedian population age increases. The potential to preserve, or evenimprove, cognition in adults at high risk of cognitive decline due to ADclearly has important implications, not only for the affectedindividual, but also for the support system that bears the social andfinancial burdens of long-term caregiving.

There are medications currently approved for symptomatic treatment ofAD, but they have small effect sizes and generally limited clinicalbenefits. An urgent need exists to find effective treatments for AD thatcan arrest or reverse the disease before its advanced stages.Therapeutic strategies aimed at restoring synaptic and extrasynapticglutamate levels, offer potential therapeutic benefit in AD, incognition, as well as in the neuroprotection of synapses, conferring thepotential for disease modification. The significance of clinicalresearch directed at this preclinically validated synaptic target cannotbe overstated, given the lack of therapeutic progress in symptomatic anddisease-modifying treatments since 2003.

The FDA originally approved riluzole (RILUTEK®) 50 mg twice-a-day (NDA#20-599) for the treatment of patients with amyotrophic lateralsclerosis (ALS). Riluzole is only indicated for ALS and has a number ofnon-desirable attributes that have limited its clinical use.

Riluzole tablets have 60% bioavailability, attributed to high first-passmetabolism in the liver. This is thought to be related to metabolism bythe heterogeneously expressed CYP1A2 enzyme, which also accounts for thehigh PK variability associated with riluzole (Carlsson, 2000; Pittenger,2015a, 2015b). In addition, riluzole is associated with reduced exposurewhen taken with meals (i.e. a negative food effect), resulting in theguidance to take riluzole within a three hour fast (one hour before ortwo hours after a meal).

Riluzole is also dosed twice a day, has dose-dependent effects on liverfunction tests and the drug substance itself has other intrinsiclimitations including: very low solubility in water, poor oralpalatability, pH dependent chemical stability, and intense oral numbnessif administered directly to the oral mucosa.

Accordingly, new compounds, pharmaceutical compositions and methods aredesired for the treatment of Alzheimer's Disease which may providebenefits for patients afflicted with the disease.

SUMMARY OF THE INVENTION

The present invention is directed to the treatment of Alzheimer'sDisease with prodrugs of riluzole. By virtue of the present invention,it may now be possible to provide more effective AD treatments topatients. Patients may experience an improved response in one or moreareas including, for example, overall survival, quality of life, overallresponse rate, duration of response, delay of onset, or patient reportedoutcome.

In one aspect of the invention, there is provided a method of treatingAD in a patient in need thereof, comprising administering to the patienta therapeutically effective amount of a riluzole prodrug.

In one aspect, the riluzole prodrug has the following formula:

and pharmaceutically acceptable salts thereof, wherein:

R₂₃ is selected from the group consisting H, CH₃, CH₂CH₃, CH₂CH₂CH₃,CH₂CCH, CH(CH₃)₂, CH₂CH(CH₃)₂, CH(CH₃)CH₂CH₃, CH₂OH, CH₂OCH₂Ph,CH₂CH₂OCH₂Ph, CH(OH)CH₃, CH₂Ph, CH₂(cyclohexyl), CH₂(4-OH-Ph),(CH₂)₄NH₂, (CH₂)₃NHC(NH₂)NH, CH₂(3-indole), CH₂(5-imidazole), CH₂CO₂H,CH₂CH₂CO₂H, CH₂CONH₂, and CH₂CH₂CONH₂.

In one aspect, the riluzole prodrug has the following formula:

In one aspect, the riluzole prodrug is administered to the patient at adosage of from about 100 to 400 mg per day.

In one aspect, the riluzole prodrug is administered to the patient at adosage of about 110, or 140, or 150, or 210, or 280, or 350 mg per day.

In one aspect, the riluzole prodrug is administered to the patient at adosage of 280 mg, once per day.

In one aspect, the riluzole prodrug is administered to the patient at adosage of 140 mg, twice per day.

In one aspect, the riluzole prodrug is administered to the patient onceper day.

In one aspect, the riluzole prodrug is administered to the patient twiceper day.

In one aspect, the riluzole prodrug is administered to the patient inthe form of a capsule.

In one aspect, the riluzole prodrug is administered to the patient inthe form of a tablet.

In one aspect, the riluzole prodrug is administered to the patient for aduration of from about 8 weeks to 48 weeks. In one aspect, the riluzoleprodrug is administered to the patient for a duration of from the onsetof treatment to the end of the patient's life.

In one aspect of the invention, there is provided a method for improvinga response in a patient afflicted with AD comprising administering tothe patient in need thereof, an effective amount of a riluzole prodrug.

In one aspect, the improved response is one or more of overall survival,quality of life, overall response rate, duration of response, delay ofonset, or patient reported outcome.

In one aspect of the invention, there is provided a kit for treating apatient afflicted with AD, the kit comprising:

(a) a riluzole prodrug; and

(b) instructions for administering the riluzole prodrug in the method ofthe invention.

In an aspect of the invention, there is provided a pharmaceuticalcomposition in the form of a capsule comprising;

(troriluzole) as an active ingredient, and pharmaceutically acceptableexcipients selected from mannitol, microcrystalline cellulose, dicalciumphosphate, hydroxypropyl cellulose, crospovidone, colloidal silicondioxide and magnesium stearate.

In an aspect of the invention, the capsule comprises from about 40-50%troriluzole, 15-20% mannitol, 3-15% microcrystalline cellulose, 3-15%dicalcium phosphate, 5-10% hydroxypropyl cellulose, 5-10% crospovidone,0.1-1% colloidal silicon dioxide and 0.1-1% magnesium stearate. Thepercentages are expressed as weight percent.

In an aspect of the invention, the capsule comprises from about 70-280mg of troriluzole, preferably 140 mg of troriluzole, 60-90 mg ofmannitol, 30-60 mg of microcrystalline cellulose, 5-20 mg of dicalciumphosphate, 5-10 mg of hydroxypropyl cellulose, 5-20 mg of crospovidone,0.5-5 mg of colloidal silicon dioxide and 0.5-5 mg of magnesiumstearate.

DETAILED DESCRIPTION OF THE INVENTION

The following detailed description is provided to aid those skilled inthe art in practicing the present invention. Those of ordinary skill inthe art may make modifications and variations in the embodimentsdescribed herein without departing from the spirit or scope of thepresent disclosure. Unless otherwise defined, all technical andscientific terms used herein have the same meaning as commonlyunderstood by one of ordinary skill in the art to which this disclosurebelongs. The terminology used in the description is for describingparticular embodiments only and is not intended to be limiting.

As used in this application, except as otherwise expressly providedherein, each of the following terms shall have the meaning set forthbelow. Additional definitions are set forth throughout the application.In instances where a term is not specifically defined herein, that termis given an art-recognized meaning by those of ordinary skill applyingthat term in context to its use in describing the present invention.

The articles “a” and “an” refer to one or to more than one (i.e., to atleast one) of the grammatical object of the article unless the contextclearly indicates otherwise. By way of example, “an element” means oneelement or more than one element.

The term “about” refers to a value or composition that is within anacceptable error range for the particular value or composition asdetermined by one of ordinary skill in the art, which will depend inpart on how the value or composition is measured or determined, i.e.,the limitations of the measurement system. For example, “about” can meanwithin 1 or more than 1 standard deviation per the practice in the art.Alternatively, “about” can mean a range of up to 10% or 20% (i.e., ±10%or ±20%). For example, about 3 mg can include any number between 2.7 mgand 3.3 mg (for 10%) or between 2.4 mg and 3.6 mg (for 20%).Furthermore, particularly with respect to biological systems orprocesses, the terms can mean up to an order of magnitude or up to5-fold of a value. When particular values or compositions are providedin the application and claims, unless otherwise stated, the meaning of“about” should be assumed to be within an acceptable error range forthat particular value or composition.

The term “administering” refers to the physical introduction of acomposition comprising a therapeutic agent to a subject, using any ofthe various methods and delivery systems known to those skilled in theart. Typical routes of administration for riluzole prodrugs include oraladministration, e.g., by capsule or tablet. Administering can also beperformed, for example, once, a plurality of times, and/or over one ormore extended periods and can be a therapeutically effective dose or asubtherapeutic dose.

The term “AUC” (area under the curve) refers to a total amount of drugabsorbed or exposed to a subject. Generally, AUC may be obtained frommathematical method in a plot of drug concentration in the subject overtime until the concentration is negligible. The term “AUC” (area underthe curve) could also refer to partial AUC at specified time intervals.

The term “Cmax” refers to a maximum concentration of a drug in blood,serum, a specified compartment or test area of a subject betweenadministration of a first dose and administration of a second dose. Theterm Cmax could also refer to dose normalized ratios if specified.

The term “dosing interval,” refers to the amount of time that elapsesbetween multiple doses of a formulation disclosed herein beingadministered to a subject. Dosing interval can thus be indicated asranges.

The term “dosing frequency” refers to the frequency of administeringdoses of a formulation disclosed herein in a given time. Dosingfrequency can be indicated as the number of doses per a given time,e.g., once a week or once in two weeks.

The term “effective amount” refers to that amount which is sufficient toeffect an intended result. The effective amount will vary depending onthe subject and disease state being treated, the severity of theaffliction and the manner of administration, and may be determinedroutinely by one of ordinary skill in the art.

The terms “in combination with” and “in conjunction with” refer toadministration of one treatment modality in addition to anothertreatment modality. As such, “in combination with” or “in conjunctionwith” refers to administration of one treatment modality before, during,or after administration of the other treatment modality to the subject.

The term “pharmaceutically acceptable salt” refers to a salt form of oneor more of the compounds or prodrugs described herein which arepresented to increase the solubility of the compound in the gastric orgastroenteric juices of the patient's gastrointestinal tract in order topromote dissolution and the bioavailability of the compounds.Pharmaceutically acceptable salts include those derived frompharmaceutically acceptable inorganic or organic bases and acids, whereapplicable. Suitable salts include those derived from alkali metals suchas potassium and sodium, alkaline earth metals such as calcium,magnesium and ammonium salts, among numerous other acids and bases wellknown in the pharmaceutical art.

The term “prodrug” refers to a precursor of a drug which may beadministered in an altered or less active form. The prodrug may beconverted into the active drug form in physiological environments byhydrolysis or other metabolic pathways. A discussion of prodrugs isprovided in T. Higuchi and V. Stella, Pro-drugs as Novel DeliverySystems (1987) 14 of the A.C.S. Symposium Series, and in BioreversibleCarriers in Drug Design, (1987) Edward B. Roche, ed., AmericanPharmaceutical Association and Pergamon Press.

The terms “subject” and “patient” refer any human or nonhuman animal.The term “nonhuman animal” includes, but is not limited to, vertebratessuch as nonhuman primates, sheep, dogs, and rodents such as mice, ratsand guinea pigs. In some embodiments, the subject is a human. The terms,“subject” and “patient” are used interchangeably herein.

The terms “therapeutically effective amount”, “therapeutically effectivedosage” and “therapeutically effective dose” of an agent (also sometimesreferred to herein as a “drug”) refers to any amount of the agent that,when used alone or in combination with another agent, protects a subjectagainst the onset of a disease or promotes disease regression evidencedby a decrease in severity of disease symptoms, an increase in frequencyand duration of disease symptom-free periods, or a prevention ofimpairment or disability due to the disease affliction. Thetherapeutically effective amount of an agent can be evaluated using avariety of methods known to the skilled practitioner, such as in humansubjects during clinical trials, in animal model systems predictive ofefficacy in humans, or by assaying the activity of the agent in in vitroassays.

The term “Tmax” refers to a time or period after administration of adrug when the maximum concentration (Cmax) is reached in blood, serum, aspecified compartment or test area of a subject.

The term “treatment” refers to any treatment of a condition or diseasein a subject and may include: (i) preventing the disease or conditionfrom occurring in the subject which may be predisposed to the diseasebut has not yet been diagnosed as having it; (ii) inhibiting the diseaseor condition, i.e., arresting its development; relieving the disease orcondition, i.e., causing regression of the condition; or (iii)ameliorating or relieving the conditions caused by the disease, i.e.,symptoms of the disease. Treatment could be used in combination withother standard therapies or alone. Treatment or “therapy” of a subjectalso includes any type of intervention or process performed on, or theadministration of an agent to, the subject with the objective ofreversing, alleviating, ameliorating, inhibiting, slowing down orpreventing the onset, progression, development, severity or recurrenceof a symptom, complication or condition, or biochemical indiciaassociated with a disease.

Riluzole is currently available in the market as RILUTEK® (riluzole) isavailable from Sanofi-Aventis, Bridgewater, N.J. and has the structureshown below.

6-(trifluoromethoxy)benzothiazol-2-amine.

Certain preferred riluzole prodrugs for use in accordance with thepresent invention have the structure:

including enantiomers, diastereomers, hydrates, solvates,pharmaceutically acceptable salts, and complexes thereof, wherein:

R₂₃ is selected from the group consisting H, CH₃, CH₂CH₃, CH₂CH₂CH₃,CH₂CCH, CH(CH₃)₂, CH₂CH(CH₃)₂, CH(CH₃)CH₂CH₃, CH₂OH, CH₂OCH₂Ph,CH₂CH₂OCH₂Ph, CH(OH)CH₃, CH₂Ph, CH₂(cyclohexyl), CH₂(4-OH-Ph),(CH₂)₄NH₂, (CH₂)₃NHC(NH₂)NH, CH₂(3-indole), CH₂(5-imidazole), CH₂CO₂H,CH₂CH₂CO₂H, CH₂CONH₂, and CH₂CH₂CONH₂. Such agents may be useful as partof the combination of the present invention.

One especially preferred riluzole prodrug, troriluzole, has thefollowing formula:

Prodrugs of riluzole are described, for example, in U.S. Pat. No.9,725,427, issued Aug. 8, 2017, U.S. patent application Ser. No.14/410,647, filed Dec. 23, 2014, U.S. patent application Ser. No.15/549,154, filed Aug. 5, 2017, PCT Application Serial No.PCT/US2016/019773, filed Feb. 26, 2016, and PCT Application Serial No.PCT/US2016/019787, filed Feb. 26, 2016.

The riluzole prodrugs may be present as isotopically labeled forms ofcompounds detailed herein. Isotopically labeled compounds havestructures depicted by the formulas given herein except that one or moreatoms are replaced by an atom having a selected atomic mass or massnumber. Examples of isotopes that can be incorporated into compounds ofthe disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen,phosphorous, fluorine and chlorine, such as, but not limited to ²H(deuterium, D), ³H (tritium), ^(n)C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸F, ³¹P, ³²P, ³⁵S,Cl and I. Various isotopically labeled compounds of the presentdisclosure, for example those into which radioactive isotopes such as³H, ¹³C and ¹⁴C are incorporated, are provided. Such isotopicallylabeled compounds may be useful in metabolic studies, reaction kineticstudies, detection or imaging techniques, such as positron emissiontomography (PET) or single-photon emission computed tomography (SPECT)including drug or substrate tissue distribution assays or in radioactivetreatment of subjects (e.g. humans). Also provided for isotopicallylabeled compounds described herein are any pharmaceutically acceptablesalts, or hydrates, as the case may be.

In some variations, the compounds disclosed herein may be varied suchthat from 1 to “n” hydrogens attached to a carbon atom is/are replacedby deuterium, in which “n” is the number of hydrogens in the molecule.Such compounds may exhibit increased resistance to metabolism and arethus useful for increasing the half life of the compound whenadministered to a subject. See, for example, Foster, “Deuterium IsotopeEffects in Studies of Drug Metabolism”, Trends Pharmacol. Sci.5(12):524-527 (1984). Such compounds are synthesized by means well knownin the art, for example by employing starting materials in which one ormore hydrogens have been replaced by deuterium.

Deuterium labeled or substituted therapeutic compounds of the disclosuremay have improved drug metabolism and pharmacokinetics (DMPK)properties, relating to absorption, distribution, metabolism andexcretion (ADME). Substitution with heavier isotopes such as deuteriummay afford certain therapeutic advantages resulting from greatermetabolic stability, for example increased in vivo half-life, reduceddosage requirements and/or an improvement in therapeutic index. An ¹⁸Flabeled compound may be useful for PET or SPECT studies. Isotopicallylabeled compounds of this disclosure can generally be prepared bycarrying out the procedures known to those skilled in the art bysubstituting a readily available isotopically labeled reagent for anon-isotopically labeled reagent. It is understood that deuterium inthis context is regarded as a substituent in the compounds providedherein.

The concentration of such a heavier isotope, specifically deuterium, maybe defined by an isotopic enrichment factor. In the compounds of thisdisclosure any atom not specifically designated as a particular isotopeis meant to represent any stable isotope of that atom. Unless otherwisestated, when a position is designated specifically as ‘H” or “hydrogen”,the position is understood to have hydrogen at its natural abundanceisotopic composition.

The riluzole prodrugs of the present invention may be given orally,sublingually, intranasally, buccally, subcutaneously or in any othersuitable means of delivery.

The dose of the riluzole prodrug to be administered may depend on thesubject to be treated inclusive of the age, sex, weight and generalhealth condition thereof. In this regard, precise amounts of theagent(s) for administration will depend on the judgment of thepractitioner. In determining the effective amount of the riluzoleprodrug to be administered in the treatment or reducing of theconditions associated with the symptoms and disorders, the physician mayevaluate clinical factors including symptoms severity or progression ofthe disorder. The effective amount of the treatment will vary dependingon the subject and disease state being treated, the severity of theaffliction and the manner of administration, and may be determinedroutinely by one of ordinary skill in the art.

The riluzole prodrug for treating AD or symptoms may be dosed at anydose effective to treat AD with a tolerable amount of side effects, ifany, for the particular patient being treated. Typical dosagefrequencies for the riluzole prodrugs include once a day, twice a day,three times a day, four times a day, once every other day, once a week,twice a week, three times a week, four times a week, once every twoweeks, once or twice monthly, and the like. Examples of dosages includeat or below about 400 mg/day, at or below about 300 mg/day, at or belowabout 150 mg/day, at or below about 100 mg/day, at or below about 70mg/day, at or below about 60 mg/day, at or below about 50 mg/day, at orbelow about 42.5 mg/day, at or below about 37.5 mg/day at or below about35 mg/day, at or below about 20 mg/day, at or below about 17.5 mg/day,at or below about 15 mg/day, at or below about 10 mg/day, at or belowabout 5 mg/day, or at or below about 1 mg/day. In one aspect, theriluzole prodrug is administered to the patient at a dosage of fromabout 110, or 140, or 150, or 210, or 280, or 350 mg per day. In oneaspect, the riluzole prodrug is administered to the patient at a dosageof 280 mg, once per day. In another aspect, the riluzole prodrug isadministered to the patient at a dosage of 140 mg, twice per day.

The pharmaceutical compositions of the present invention comprising theriluzole prodrug typically also include other pharmaceuticallyacceptable carriers and/or excipients such as binders, lubricants,diluents, coatings, disintegrants, barrier layer components, glidants,coloring agents, solubility enhancers, gelling agents, fillers,proteins, co-factors, emulsifiers, solubilizing agents, suspendingagents and mixtures thereof. A skilled artisan in the art would knowwhat other pharmaceutically acceptable carriers and/or excipients couldbe included in the formulations according to the invention. The choiceof excipients would depend on the characteristics of the compositionsand on the nature of other pharmacologically active compounds in theformulation. Appropriate excipients are known to those skilled in theart (see Handbook of Pharmaceutical Excipients, fifth edition, 2005edited by Rowe et al., McGraw Hill) and have been utilized to yield anovel sublingual formulation with unexpected properties.

Examples of pharmaceutically acceptable carriers that may be used inpreparing the pharmaceutical compositions of the present invention mayinclude, but are not limited to, fillers such as sugars, includinglactose, sucrose, mannitol, or sorbitol; cellulose preparations such asmaize starch, wheat starch, rice starch, potato starch, gelatin, gumtragacanth, methyl cellulose, hydroxypropyl methyl-cellulose, sodiumcarboxymethylcellulose, polyvinyl-pyrrolidone (PVP), talc, calciumsulphate, vegetable oils, synthetic oils, polyols, alginic acid,phosphate buffered solutions, emulsifiers, isotonic saline, pyrogen-freewater and combinations thereof. If desired, disintegrating agents may becombined as well, and exemplary disintegrating agents may be, but notlimited to, cross-linked polyvinyl pyrrolidone, agar, or alginic acid ora salt thereof such as sodium alginate. The compositions may be preparedby any of the methods of pharmacy but all methods include the step ofbringing into association one or more chemical agents as described abovewith the carrier which constitutes one or more necessary ingredients. Ingeneral, the pharmaceutical compositions of the present invention may bemanufactured in conventional methods known in the art, for example, bymeans of conventional mixing, dissolving, granulating, dragee-making,levigating, emulsifying, encapsulating, entrapping, lyophilizingprocesses and the like.

In one aspect of the invention, the riluzole prodrug is provided in aform of an orally dissolving or disintegrating tablet (ODT) forsublingual administration. In general, the excipients, includingmannitol and gelatin, are blended, solubilized with water and deaeratedbefore being mixed with the active pharmaceutical ingredient (API),which has been milled separately. The particle size of the API (D50) isless preferably than about 2 microns. The mixture is lyophilized byflash freezing and then freeze-dried. The effective amount of riluzoleprodrug for the sublingual formulation useful in the present inventionto achieve a therapeutically effective dose may be less than that oforally administered agent. For example, the effective dose of thesublingual formulation of the riluzole prodrug may be about 1 to 95%,preferably 50 to 90%, more preferably 70 to 85% and most preferablyabout 80% of that of the orally administered agent in a conventionaltablet or capsule. In one aspect of the invention, the pharmaceuticalcompositions are prepared in an ODT form as described in U.S. Pat. No.9,192,580, issued Nov. 24, 2015. ODT dosage forms are further describedby Gregory et al., U.K. Patent No. 1,548,022 using fish gelatin as thecarrier. Fish gelatins suitable for use in the invention arecommercially available.

Typically, the ODT dosage form disintegrate or disperse within 1 to 60seconds, preferably 1 to 30 seconds, more preferably 1 to 10 seconds andparticularly 2 to 8 seconds, after being placed in contact with a fluid.The fluid is preferably that found in the oral cavity, i.e., saliva, aswith oral administration.

The ODT compositions according to the invention can also contain, inaddition to the active ingredient arid fish gelatin carrier, othermatrix forming agents and secondary components. Matrix forming agentssuitable for use in the present invention include materials derived fromanimal or vegetable proteins, such as other gelatins, dextrins and soy,wheat and psyllium seed proteins; gums such as acacia, guar, agar, and10 xanthan; polysaccharides; alginates; carboxymethylcelluloses;carrageenans; dextrans; pectins; synthetic polymers such aspolyvinylpyrrolidone; and polypeptide/protein or polysaccharidecomplexes such as gelatin-acacia complexes.

Other materials which may also be incorporated into the ODT compositionsof the present invention include sugars such as mannitol, dextrose,lactose, galactose, and trehalose; cyclic sugars such as cyclodextrin;inorganic salts such as sodium phosphate, sodium chloride and aluminumsilicates; and amino acids having from 2 to 12 carbon atoms such asglycine, L-alanine, L-aspartic acid, L-glutamic acid, L-hydroxyproline,L-isoleucine, L-leucine and L-phenylalanine. One or more matrix formingagents may be incorporated into the solution or suspension prior tosolidification (freezing). The matrix forming agent may be present inaddition to a surfactant or to the exclusion of a surfactant. Inaddition to forming the matrix, the matrix forming agent may aid inmaintaining the dispersion of any active ingredient within the solutionof suspension. This is especially helpful in the case of active agentsthat are not sufficiently soluble in water and must, therefore, besuspended rather than dissolved. Secondary components such aspreservatives, antioxidants, surfactants, viscosity enhancers, coloringagents, flavoring agents, pH modifiers, sweeteners or taste-maskingagents may also be incorporated into the fast-dissolving compositions.Suitable coloring agents include red, black and yellow iron oxides andFD & C dyes such as FD&C Blue No. 2 and FD&C Red No. 40 available fromEllis & Everard. Suitable flavoring agents include mint, raspberry,licorice, orange, lemon, grapefruit, caramel, vanilla, cherry and grapeflavors and combinations of these. Suitable pH modifiers include theedible acids and bases, such as citric acid, tartaric acid, phosphoricacid, hydrochloric acid, maleic acid and sodium hydroxide. Suitablesweeteners include, for example, sucralose, aspartame, acesulfame K andthaumatin. Suitable taste-masking agents include, for example, sodiumbicarbonate, ion exchange resins, cyclodextrin inclusion compounds,adsorbates or microencapsulated actives.

In a preferred aspect of the invention, the ODT compositions comprisesfrom about 50-70 wt % riluzole prodrug, about 10-30 wt % fish gelatin,about 10-20 wt % of one or more fillers, and 0.1-5.0 wt % of one or moreflavorants.

Other methods of preparing ODTs may be used without limitation, anddetailed description of general methods thereof have been disclosed, forexample, in U.S. Pat. Nos. 5,631,023; 5,837,287; 6,149,938; 6,212,791;6,284,270; 6,316,029; 6,465,010; 6,471,992; 6,471,992; 6,509,040;6,814,978; 6,908,626; 6,908,626; 6,982,251; 7,282,217; 7,425,341;7,939,105; 7,993,674; 8,048,449; 8,127,516; 8,158,152; 8,221,480;8,256,233; and 8,313,768.

In a preferred aspect of the invention, there is provided apharmaceutical composition in the form of a capsule comprising;

(troriluzole) as an active ingredient, and pharmaceutically acceptableexcipients selected from mannitol, microcrystalline cellulose, dicalciumphosphate, hydroxypropyl cellulose, crospovidone, colloidal silicondioxide and magnesium stearate. In an aspect of the invention, thecapsule comprises from about 40-50% troriluzole, 15-20% mannitol, 3-15%microcrystalline cellulose, 3-15% dicalcium phosphate, 5-10%hydroxypropyl cellulose, 5-10% crospovidone, 0.1-1% colloidal silicondioxide and 0.1-1% magnesium stearate. The percentages are expressed asweight percent. In an aspect of the invention, the capsule comprisesfrom about 70-280 mg of troriluzole, preferably 140 mg of troriluzole,60-90 mg of mannitol, 30-60 mg of microcrystalline cellulose, 5-20 mg ofdicalcium phosphate, 5-10 mg of hydroxypropyl cellulose, 5-20 mg ofcrospovidone, 0.5-5 mg of colloidal silicon dioxide and 0.5-5 mg ofmagnesium stearate. Techniques for manufacturing capsules suitable foruse in accordance with the present invention are known to those skilledin the art.

In an embodiment, provided is a method of treating mild Alzheimer'sDisease in a patient in need thereof, which includes administering tothe patient a therapeutically effective amount of a riluzole prodrug.Mild Alzheimer's Disease is an early stage Alzheimer's Disease, where aperson may still function independently. She or he may drive, work andbe part of social activities. Despite this, the person may feel as ifshe or he is having memory lapses, such as forgetting familiar words orthe location of everyday objects. Symptoms may not be widely apparent atthis stage, but family and close friends may take notice and a doctorwould be able to identify symptoms using certain diagnostic tools.Common difficulties may include coming up with the right word or name,remembering names when introduced to new people, having difficultyperforming tasks in social or work settings, forgetting material thatwas just read, losing or misplacing a valuable object, and experiencingincreased trouble with planning or organizing. More information aboutthe stages of Alzheimer's Disease may found athttps://www.alz.org/alzheimers-dementia/stages.

Also within the scope of the present invention are kits comprising ariluzole prodrug (e.g., troriluzole) for therapeutic uses. Kitstypically include a label indicating the intended use of the contents ofthe kit and instructions for use. The term label includes any writing,or recorded material supplied on or with the kit, or which otherwiseaccompanies the kit.

EXAMPLES

The following examples illustrate the invention and are not intended tolimit the scope of the invention.

Example 1

A clinical study is conducted with the following parameters. Foradditional information, refer to ClinicalTrials.gov IdentifierNCT03605667, www.clinicaltrials.gov.

Study Description Brief Summary

Preclinical models suggest that riluzole, the active metabolite ofBHV-4157, may protect from AD-related pathology and cognitivedysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, takenorally once daily. Duration of treatment is 48 weeks. There is also ascreening period of up to 42 days; and a 4-week post-treatmentobservation period.

Condition or disease Intervention/treatment Phase Alzheimer DiseaseDrug: troriluzole Drug: Phase 2/Phase 3 Placebo oral capsule

Study Design

Study Type: Interventional (Clinical Trial) Estimated Enrollment: 292participants Allocation: Randomized Intervention Model: ParallelAssignment Masking: None (Open Label) Primary Purpose: TreatmentOfficial Title: A Phase 2 Randomized Double-Blind Placebo- ControlledTrial to Evaluate the Efficacy and Safety of BHV-4157 in Patients WithMild to Moderate Alzheimer's Disease

Arms and Interventions

Arm Intervention/treatment Experimental: BHV-4157 Drug: troriluzoletroriluzole, 280 mg capsules, QD Oral BHV-4157 will be given daily forup to 48 weeks Other Name: BHV-4157 Placebo Comparator: Placebo matchingDrug: Placebo oral capsule 280 mg placebo capsules, QD Oral matchingplacebo will be given daily for up to 48 weeks

Outcome Measures Primary Outcome Measures:

1. The change in Alzheimer's Disease Assessment Scale Cognitive Subscale(ADAS-Cog 11) from baseline to week 48 between the BHV-4157 treatmentgroup and the placebo group [Time Frame: Baseline to Week 48]

Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog 11)

The ADAS-Cog 11 evaluates memory (word recall, word recognition),reasoning (following commands), language (naming, comprehension),orientation, ideational praxis (placing a letter in an envelope) andconstructional praxis (copying geometric designs). Ratings of spokenlanguage, language comprehension, word finding difficulty, and abilityto remember test instructions are also obtained. The test is scored interms of errors, with higher scores reflecting poorer performance andgreater impairment. Scores can range from 0 (best) to 70 (worse).

Eligibility Criteria

Ages Eligible for Study: 50 Years to 85 Years (Adult, Older Adult) SexesEligible for Study: All Accepts Healthy Volunteers: No

Criteria

Key Inclusion Criteria:

-   -   Age 50 to 85 (inclusive) at screening    -   Diagnosed with probable Alzheimer's disease dementia: Core        clinical criteria in accordance with NIA/Alzheimer's Association        Guidelines.    -   Living in the community (includes assisted living facilities,        but excludes long-term care nursing facilities).    -   Ambulatory, or able to walk with an assistive device, such as a        cane or walker.    -   Participants must have a study partner who has frequent        interaction with them (approximately >3-4 times per week), will        be present for all clinic visits, and can assist in compliance        with study procedures.    -   A brain MRI scan within 6 months of screening consistent with a        diagnosis of Alzheimer's disease.    -   Participants should be treated with a stable dosage regimen of        FDA-approved AD medications (acetylcholinesterase inhibitors        (AchEI) and/or memantine) for at least 3 months prior to        screening. Participants should be expected to remain on a stable        dosage regimen of these medications for the duration of the        trial.    -   Participants who are not being treated with FDA-approved AD        medications at the time of screening, because they have        contraindications to these medications, or because they have        previously failed treatment with these medications, are also        eligible for inclusion, if it is expected that they will not be        treated with these medications for the duration of the trial.

Key Exclusion Criteria:

-   -   Hepatic impairment defined as Child-Pugh class of A or more        severe liver impairment.    -   Other neurodegenerative diseases and causes of dementias,        including Parkinson's disease and Huntington's disease, vascular        dementia, CJD (Creutzfeldt-Jakob disease), LBD (Lewy Body        dementia), PSP (Progressive Supranuclear Palsy), AIDS (Acquired        Immunodeficiency Syndrome), or NPH (normal pressure        hydrocephalus).    -   History of a major depressive episode within the past 6 months        of screening.    -   Insulin-dependent diabetes or uncontrolled diabetes with HbAlc        value >8.0%.    -   Cancer or a malignant tumor within the past 3 years, except        patients who underwent potentially curative therapy with no        evidence of recurrence for >3 years. Patients with stable        prostate cancer or non-melanoma skin cancers are not excluded.    -   Participation in another clinical trial for an investigational        agent and having taken at least one dose of study medication,        unless confirmed as having been on placebo, within 12 weeks        prior to screening. The end of a previous investigational trial        is defined as the date of the last dose of an investigational        agent.

Example 2

A clinical study is conducted with the following parameters.

Study Summary

Title A Phase 2 Randomized Double-Blind Placebo-Controlled Trial toEvaluate the Efficacy and Safety of BHV-4157 in Patients with Mild toModerate Alzheimer's Disease Rationale BHV-4157 is a new chemical entity3rd-generation prodrug of the glutamate modulator, riluzole, which hasbeen designed to bypass first-pass metabolism therein providing greaterbioavailability, diminished PK variability, lower hepatic burden, lackof food effect, longer half-life and once daily dosing. Preclinicalmodels suggest that riluzole, the active metabolite of BHV-4157, mayprotect from AD-related pathology and cognitive dysfunction. Target Maleand females, age 50 to 85 years (inclusive at screening), diagnosed withPopulation Alzheimer's Disease (in accordance with NIA/Alzheimer'sAssociation Guidelines) of mild to moderate severity including MMSEscore 14-24 at the screening visit. Eligible participants should bereceiving a stable dose of FDA-approved AD medication(s)(acetylcholinesterase inhibitors (AchEI) and/or memantine) for at least3 months prior to screening and willing to remain on same dose(s) fortrial duration. Those participants with contraindications or failedtreatment with either AchEI and/or memantine will be eligible forinclusion. Number of Approximately 292 participants will be randomlyallocated using a 1:1 allocation Participants to active treatment orplacebo. Drug Dosage & Titrated dose of BHV-4157 to 280 mg, or placebo,taken orally once daily. Treatment Duration of treatment is 48 weeks.There is also a screening period of up to 42 Duration days; and a 4-weekpost-treatment observation period. Objectives The primary objective isto: evaluate the efficacy of BHV-4157 as measured by the ADAS-Cog 11.The key secondary objective is to: evaluate the efficacy of BHV-4157 asmeasured by the CDR-Sum of Boxes. The secondary objectives are to: (1)evaluate the efficacy of BHV-4157 as measured by: Quarc volumetric MRI(bilateral hippocampal volume, bilateral lateral ventricles, and wholebrain volume), Neuropsychiatric Inventory (NPI), ADCS-ADL,neuropsychological test battery (Craft Story 21 Recall (Immediate &Delayed), Benson Figure (Copy & Delayed Recall), Multilingual NamingTest (MINT), Letter & Category Fluency, Trail Making Test A & B, NumberSpan Forward & Backward), Mini-Mental State Examination (MMSE), andMontreal Cognitive Assessment (MoCA); (2) evaluate the safety andtolerability of BHV- 4157 as measured by mortality rates, seriousadverse events, adverse events, clinical safety laboratories, physicalexaminations and significant ECG changes. Exploratory objectives are to:(1) assess pharmacokinetics of BHV-4157 (2) assess treatment response inparticipants with typical vs. atypical Alzheimer's disease presentationas well as by Apo E genotype; (3) evaluate a panel of CSF, serum andplasma biomarkers (AB42, AB42/40 ratio, total tau, p-tau, neurogranin,NfL, YKL-40, VILIP, SNAP-25, sTREM2) in a subset of the study population(estimated n = 50 active, n = 50 placebo) at screening, week 24 and week48. Study Design & This is a phase 2 multi-center, randomized, doubleblind, placebo-controlled, Statistical Plan parallel group study. MMSEscore (14 to 19; 20 to 24) at screening and Site will be stratificationfactors. An Interim Futility Analysis for proof-of-concept will beconducted when a sentinel cohort consisting of the first 50 randomizedparticipants in each arm has received 24 weeks of treatment or longer onstudy (completers only analysis). At this point, an interim data freeze(database snapshot) will take place and the analyses will be conductedusing the frozen data set. The study will continue if any one of thefollowing conditions is met, using a one- sided test at the statedsignificance level: Mean change from baseline to interim analysis onADAS-Cog 11: Treatment Control is significantly improved at the p ≤ 0.50level. Mean change from screening to interim analysis on MRI Quarchippocampal volume: Treatment-Control is significantly improved at the p≤ 0.20 level. If both conditions fail, the DSMB will indicate thatfutility criteria have been met to the Study Steering Committee (SSC)who are overseeing the trial. The SSC will have the final responsibilityfor the decision to stop the trial. This interim analysis is designed tostop with a probability of 40% under the assumption that the twoendpoints are independent and that there is no true difference betweenarms in both of the interim measures above. Overall study power at thefinal analysis: Given that the interim analysis has power of 86%, andthat the interim and final endpoints have correlation of at least 20%,the overall study has 80% power to detect a difference of 2.5 points onthe ADAS-Cog 11 at week 48 (SD 6 points), at two-sided 5% significancelevel. At the final analysis, there is also 80% power to detect a meanincrease of 0.9 points on CDR-SOB (key secondary endpoint) at 48 weeks,which corresponds to a decline in the active arm of about 40% or less ofthe placebo arm decline. The primary and key secondary endpoints at thefinal analysis will be tested using a hierarchical gatekeeper strategy:if ADAS-Cog 11 is significant at the 5% level, then CDR-SOB will also betested at 5% significance level. If both primary and key secondaryoutcomes are significant, the remainder of the secondary outcomes willbe tested at overall 5% significance level using a Holm's step downtest. This will preserve alpha at 5% overall for all endpoints tested.Statistical methods: Both the interim and final analysis will use amixed effects repeated measures model. Primary The change in ADAS-Cog 11from baseline to week 48 between the BHV-4157 Endpoint treatment groupand the placebo group. Secondary The change in CDR-Sum of Boxes frombaseline to week 48 between the BHV- Endpoints 4157 treatment group andthe placebo group. The change in MRI Quarc bilateral hippocampal volume,bilateral lateral ventricles, and whole brain volume from screening toweek 48. The change in the NPI total score from baseline to weeks 24 and48. The change in ADCS-ADL from baseline to weeks 24 and 48. The changein composite score from baseline to week 48 on the neuropsychologicaltest battery (Craft Story 21 Recall (Immediate & Delayed), Benson Figure(Copy & Delayed Recall), Multilingual Naming Test (MINT), Letter &Category Fluency, Trail Making Test A & B, Number Span Forward &Backward). The change in MMSE from baseline to weeks 24 and 48. Thechange in MoCA scores from baseline to weeks 24 and 48. The change insafety and tolerability measures including: (1) adverse events; (2)clinical laboratory tests; (3) vital signs; (4) physical examinations;(5) ECGs.

LIST OF ABBREVIATIONS

Aβ β-Amyloid

AchEI Acetylcholinesterase Inhibitor

AD Alzheimer's Disease

ADAS-Cog Alzheimer's Disease Assessment Scale-Cognitive (subscale)

ADCS-ADL Alzheimer's Disease Cooperative Study-Activities of DailyLiving Inventory

ADME Absorption, Distribution, Metabolism, Excretion

AICD Automatic Implanted Cardioverter Defibrillator

AUC Area Under the Curve

AE Adverse Event

AIDS Acquired Immunodeficiency Syndrome

ALS Amyotrophic Lateral Sclerosis

ALT Alanine Aminotransferase

ApoE Apolipoprotein E

AST Aspartate Aminotransferase

BDNF Brain-derived Neurotrophic Factor

BID Twice per day

BUN Blood Urea Nitrogen

CDR-SOB Clinical Dementia Rating Sum of Boxes

CFR Code of Federal Regulations

CJD Creutzfeldt-Jakob Disease

CONSORT Consolidated Standards of Reporting Trials

CPK Creatinine Phosphokinase

CSF Cerebrospinal Fluid

CYP Cytochrome P450

DMP Data Management Plan

DSM Diagnostic and Statistical Manual of Mental Disorders

DSMB Data Safety & Monitoring Board

eCRF Electronic Case Report Form

ECG Electrocardiogram

EDC Electronic Data Capture

FDA Food & Drug Administration

GCP Good Clinical Practice

GGT Gamma-Glutamyl Transferase

GMP Good Manufacturing Practice

HCV Hepatitis C Virus

HDL High-Density Lipoprotein

HIPAA Health Insurance Portability & Accountability Act

hr (unit) Hour

ICF Informed Consent Form

ICH International Conference on Harmonization

IRB Institutional Review Board

ITT Intent-To-Treat

kg (unit) Kilogram

LAR Legally Authorized Representative

LBD Lewy Bodies Dementia

LDH Lactate Dehydrogenase

LDL Low-Density Lipoprotein

LFT Liver Function Test

LP Lumbar Puncture

MAD Multiple Ascending Dose

MCI Multiple Cerebral Infarctions

MINT Multi-lingual Naming Test

mITT Modified Intent-To-Treat

mg (unit) Milligram

ml (unit) Milliliter

MMSE Mini-Mental State Examination

MoCA Montreal Cognitive Assessment

MRI Magnetic Resonance Imaging

NfL Neurofilament Light (Protein)

ng (unit) Nanogram

NIA National Institute on Aging

NOAEL No-observed-adverse-effect-level

NPH Normal Pressure Hydrocephalus

NPI Neuropsychiatric Inventory

OHRP Office of Human Research Protection

PHI Personal Health Information

PI Principal Investigator

PK Pharmacokinetic

PP Per Protocol

PSP Progressive Supranuclear Palsy

QD Once per day

Quarc Quantitative Anatomical Regional Change

RBC Red Blood Cell

SAD Single Ascending Dose

SAE Serious Adverse Event

SAP Statistical Analysis Plan

SCA Spinocerebellar Ataxia

SD Standard Deviation

SSC Study Steering Committee

sTREM2 Soluble Variant Triggering Receptor Expressed on Myeloid Cells 2

ULN Upper Limit of Normal

USPI United States Prescribing Information

VILIP Visinin-Like Protein

vMRI Volumetric Magnetic Resonance Imaging

WBC White Blood Cell

1 Study Design

This is a phase 2 multi-center, randomized, double blind,placebo-controlled, parallel group study in patients with mild tomoderate Alzheimer's disease.

Participants will be randomized to one of two groups: 280 mg of BHV-4157or placebo. The BHV-4157 treatment dose of 280 mg was selected forevaluation in the current study based on evidence summarized in Section1.8. Treatment duration is 48 weeks (12 months). There is a screeningperiod of up to 42 days and a 4-week post-treatment observation period.

An interim analysis for futility will be conducted when a sentinelcohort consisting of the first 50 randomized participants in each armhas received 24 weeks of treatment or longer on study (completers onlyanalysis). The interim analysis is based on the change, from baseline toweek 24, of two measures, including: the surrogate primary endpoint(ADAS-Cog 11) and hippocampal volume change.

2 Objectives

2.1 Primary Objective

The primary objective is to evaluate the efficacy of BHV-4157 asmeasured by ADAS-Cog 11.

2.2 Secondary Objectives

The secondary objectives are to evaluate the efficacy, safety andtolerability of BHV-4157 as outlined below.

2.2.1 Efficacy

The efficacy of BHV-4157 will be assessed by the following measures:

-   -   CDR-Sum of Boxes (key secondary objective),    -   Volumetric MRI (Quarc bilateral hippocampal volume, bilateral        lateral ventricles, and whole brain volume),    -   Neuropsychiatric Inventory (NPI),    -   Alzheimer's Disease Cooperative Study (ADCS)-Activities of Daily        Living (ADCS-ADL),    -   Neuropsychological test battery (Craft Story 21 Recall        (Immediate & Delayed), Benson Complex Figure (Copy & Delayed        Recall), Multi-lingual Naming Test (MINT), Letter & Category        Fluency, Trail Making Test A & B, Number Span Forward and        Backward),    -   Mini-Mental State Examination (MMSE), and    -   Montreal Cognitive Assessment (MoCA).

2.2.2 Safety and Tolerability

The safety and tolerability of BHV-4157 will be assessed by thefollowing measures:

-   -   Mortality rates,    -   Serious adverse event rates,    -   Adverse events,    -   Clinical safety laboratories,    -   Vital signs,    -   Physical examinations,    -   ECGs, and    -   Use of concomitant medications.

3 Endpoints

3.1 Primary Endpoint

The primary efficacy endpoint is the within-participant change inADAS-Cog 11 from baseline to week 48, compared between the treatmentgroup and the placebo group.

3.2 Secondary Endpoints

The secondary endpoints will measure the efficacy, and safety andtolerability of BHV-4157 as outlined below.

3.2.1 Efficacy

The efficacy of BHV-4157 will be assessed by the within-participantchanges from baseline to week 48, compared between the treatment groupand the placebo group, on the following:

-   -   CDR-Sum of Boxes (key secondary endpoint),    -   Volumetric MRI (Quarc bilateral hippocampal volume, bilateral        lateral ventricles, and whole brain volume)    -   Neuropsychiatric Inventory (NPI) scores    -   Alzheimer's Disease Cooperative Study (ADCS)-Activities of Daily        Living (ADCS-ADL) scores    -   Neuropsychological test battery scores (Craft Story 21 Recall        (Immediate & Delayed), Benson Complex Figure (Copy & Delayed        Recall), Multi-lingual Naming Test (MINT), Letter & Category        Fluency, Trail Making Test A & B, Number Span Forward and        Backward),    -   Mini-Mental State Examination (MMSE) scores, and    -   Montreal Cognitive Assessment (MoCA) scores.

3.2.2 Safety and Tolerability

The following safety and tolerability measures will be assessed fordifferences between the treatment group and the placebo group:

-   -   Occurrence of mortality events,    -   Occurrence of serious adverse events (SAEs),    -   Occurrence of adverse events (AEs),    -   Clinical laboratory tests,    -   Vital signs,    -   Physical examinations,    -   ECGs, and    -   Use of concomitant medications.

4 Study Drug

4.1 Study Medication

The study medication will be presented as one of the following:

-   -   BHV-4157, 1 or 2 capsules (size 1) of 140 mg each, depending on        assigned dose    -   1 or 2 capsules of matching Placebo

The study medication capsule should not be opened.

The study medication will be securely stored at the study site inaccordance with the conditions specified on the label, separately fromother drugs. The study medication may not be used for any purpose otherthan this study.

4.2 Blinding

This is a double-blind placebo-controlled trial. Treatments will beblinded to the participants and study personnel throughout the study.Treatment blind will be maintained by use of matching placebomedication.

Only in the case of an emergency, when knowledge of whether theparticipant has received the investigational product is essential forthe clinical management or welfare of the participant, may theInvestigator unblind a participant's treatment assignment. Proceduresfor emergency unblinding are initiated by contacting the ADCS MedicalMonitor.

5 Patient Selection

5.1 Inclusion Criteria

Participants must meet all of the following inclusion criteria to beeligible for enrollment:

-   -   1. Age 50 to 85 (inclusive) at screening    -   2. Diagnosed with probable Alzheimer's disease dementia: Core        clinical criteria in accordance with NIA/Alzheimer's Association        Guidelines.    -   3. Living in the community (includes assisted living facilities,        but excludes long-term care nursing facilities).    -   4. Ambulatory, or able to walk with an assistive device, such as        a cane or walker.    -   5. Participants must have a study partner who has frequent        interaction with them (approximately >3-4 times per week), will        be present for all clinic visits, and can assist in compliance        with study procedures.    -   6. Female patients must be post-menopausal for at least 2        consecutive years or surgically sterile (bilateral tubal        ligation, hysterectomy or bilateral oophorectomy) for at least 6        months prior to screening.    -   7. A modified Hachinski score of 4 or less at screening.    -   8. An MMSE score of 14 to 24, inclusive, at screening.    -   9. A brain MRI scan within 6 months of screening consistent with        a diagnosis of Alzheimer's disease.    -   10. Body mass index (BMI) 35 kg/m² at screening.    -   11. Participants should be treated with a stable dosage regimen        of FDA-approved AD medications (acetylcholinesterase inhibitors        (AchEI) and/or memantine) for at least 3 months prior to        screening. Participants should be expected to remain on a stable        dosage regimen of these medications for the duration of the        trial.        -   a. Participants who are not being treated with FDA-approved            AD medications at the time of screening, because they have            contraindications to these medications, or because they have            previously failed treatment with these medications, are also            eligible for inclusion, if it is expected that they will not            be treated with these medications for the duration of the            trial.    -   12. Ability (patients and their study partners) to read, speak        and understand English or Spanish to ensure compliance with        cognitive testing and study visit procedures.    -   13. Provision of informed consent from the participant (or the        participant's legally authorized representative (LAR) if unable        to provide consent) and the study partner.

5.2 vMRI Assessments

Brain structural change is seen in normal aging, but is accelerated inneurodegenerative disease, including AD. Atrophy in AD arises fromneuron and synapse loss that begins in the entorhinal cortex. Thepathology then spreads throughout the limbic regions of the temporallobe, including the hippocampal formation. Subsequently, neuron loss andatrophy is observed throughout neocortical association areas intemporal, parietal and frontal lobes.

vMRI allows the in vivo assessment of brain structure volume andprovides a measure of atrophy rate. Results from vMRI studies suggestthat the patterns of atrophy in AD, which mirror the pathologicalprogression of the disease, can reliably be detected and tracked acrosstime. Atrophy of the medial temporal lobe, including hippocampus andentorhinal cortex, has long been described in vMRI studies of AD.Hippocampal volume derived from MRI correlates with histologicalhippocampal volume and degree of neuronal loss and AD pathology, andentorhinal cortical thickness change appears to be an early andsensitive indicator of neurodegeneration associated with AD (Holland etal., 2009; Jack et al., 2004). Longitudinal MRI measures of regional andwhole-brain volumetric change provide a valuable complement to cognitivemeasures in that they are not influenced by temporary symptomaticimprovements, and they provide an early index of the study drug'sability to reach the target organ and have an effect on AD-relatedatrophy.

Participants will undergo vMRI scans of the brain at screening, week 24and week 48 in order to assess for changes in brain volumes that may beassociated with clinical change due to treatment with BHV-4157.

Volumetric MRI scans will use the same imaging protocol, which willinclude a localizer scan, a 3D T1weighted sagittal acquisition (MPRAGEor IR-SPGR), a T2-weighted FLAIR axial acquisition, a T2* gradientrecalled echo axial acquisition for magnetic susceptibility, and adiffusion weighted axial acquisition to assess for restricted diffusion.

Images will be checked for image quality and adherence to scanningprotocols. 3D T1-weighted datasets passing quality checks will becorrected for spatial distortion and for intensity variation. Screeningand follow-up datasets for each participant will be spatially registeredto one another using rigid-body registration followed by nonlinearregistration and neuroanatomic parcellation to quantify whole-brain andsubregional volumetric change on a patient-by patient basis.

The local MRI results will determine eligibility for each participant inthe trial. It is It is the responsibility of the PI to make thisdetermination following review of the MRI, and to sign as well as datethe local report to acknowledge their review, and to confirm that theMRI results are consistent with AD and do not meet exclusion criteria.The PI is at liberty to consult with a local neuroradiologist, howeverthere is no requirement for a formal MRI read from a neuroradiologist.The ADCS Medical Safety team, or ADCS Imaging core are available toaddress any questions surrounding MRI eligibility. If there are safetyconcerns are identified on this MRI, the PI should communicate with theparticipant's Primary Care Physician and consult with ADCS MedicalMonitor, ADCS Director, and ADCS Imaging Core.

Whole brain volume (WBV, excluding cerebellum), bilateral ventricularvolume and bilateral hippocampal volume will be measured. Quantitativeanatomical regional change (Quarc) will be used as the computational MRimage processing application. Detail for the statistical computations isgiven in the Statistical Analytical Plan (SAP).

If performed on the same day as a lumbar puncture, the vMRI should beconducted before the lumbar puncture. Otherwise, at least a 3-day windowbetween vMRI and the lumbar puncture is required. Scanners that havepassed the study's qualification procedures will be used. Participantsmust be scanned by the same scanner throughout the study.

Participants with a contraindication to MRI at the time of screening aredeemed ineligible to participate in this study. Participants maycontinue to participate on the study if they have already beenrandomized but develop a contraindication to MRI during the course ofthe study.

5.3 CSF, Serum and Plasma Substudy Assessments

CSF, serum and plasma will be taken at screening within 14 days prior tofirst dose of study drug and within 14 days prior to weeks 24 and 48 tomeasure biomarkers (Aß42, Aß42/40 ratio, total tau, p-tau, neurogranin,NfL, YKL-40, VILIP, SNAP-25, sTREM2).

CSF samples should be collected at the same time of day, either morning(between 8 and 10 AM) or afternoon (between 1 and 3 PM). The firstlumbar puncture must be conducted prior to initiation of study drug.Plasma samples for PK should be drawn at the time of lumbar puncture.Date and time of doses on the day of lumbar puncture and day priorshould be collected in case report forms, for entry into the EDC system.

The estimated 100 participants (n=50 active, n=50 placebo) who arewithin the sentinel cohort that constitute the study sample for thefutility analysis will also have the opportunity to participate in aCSF, serum, and plasma substudy, with samples drawn in the screeningperiod and at week 24, with the option for a third sampling timepoint atweek 48.

In addition to the sentinel substudy participants, other consentingtrial participants will be approached to undergo a blood draw to provideserum and plasma biomarkers. For CSF, consenting participants willundergo a lumbar puncture at screening within 14 days prior to firstdose of study drug and within 14 days prior to week 48 to measure theCSF biomarkers. Anti-platelet and anticoagulant medications and lumbarpuncture are addressed above in in (Prohibited Concomitant Medications.Participants who are taking anticoagulants or dual antiplatelet drugsare excluded from the CSF substudy.

Details of the CSF Sampling are Contained in the Study ProceduresManual.

The unused portion of CSF may be transferred to the National CellRepository for Alzheimer's Disease (NCRAD) for future research.Participants will be given the choice to allow such sample retention andfurther investigation of their CSF.

6 Study-Specific Instruments

6.1 Cognitive Measures

6.1.1 Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog11)

The ADAS-Cog 11 (Rosen, Mohs, & Davis, 1984) is a structured scale thatevaluates memory (word recall, word recognition), reasoning (followingcommands), language (naming, comprehension), orientation, ideationalpraxis (placing a letter in an envelope) and constructional praxis(copying geometric designs). Ratings of spoken language, languagecomprehension, word finding difficulty, and ability to remember testinstructions are also obtained. The test is scored in terms of errors,with higher scores reflecting poorer performance and greater impairment.Scores can range from 0 (best) to 70 (worse).

6.1.2 Mini-Mental State Examination (MMSE)

The MMSE is a frequently used screening instrument for Alzheimer'sdisease drug trials. It evaluates orientation, memory, attention,concentration, naming, repetition, comprehension, and ability to createa sentence and to copy two intersecting pentagons (Folstein, Folstein, &McHugh, 1975). A lower score indicates more cognitive impairment. Thehighest (best) score is 30.

6.1.3 Montreal Cognitive Assessment (MoCA)

The MoCA is a brief mental status exam which was designed to be moresensitive to mild cognitive impairment and early dementia than the MMSE(Nasreddine et al., 2005). It assesses numerous cognitive domains,including attention and concentration, executive functions, memory,language, visuoconstructional skills, conceptual thinking, calculations,and orientation. Like the MMSE, the highest (best) score is 30.Administering both the MoCA and the MMSE in this trial will allowcomparisons of the utility within the setting of a clinical trial.

6.1.4 Neuropsychological Test Battery (NTB)

The neuropsychological battery from the Uniform Data Set (v3.0—Form C2)of the National Alzheimer's Coordinating Center (NACC) (Weintraub etal., 2009) will be administered to provide a more detailed assessment ofcognition. The battery includes brief measures of attention, processingspeed, executive function, episodic memory, and language. Exploratoryanalyses will classify participants as typical (i.e., prominent memoryimpairment) or atypical (i.e., relative sparing of memory) based uponpattern of performance on the neuropsychological test battery atbaseline. As described in the manual for test administration and scoring(Version 3.0, March 2015), Form C2 of the NACC UDS battery includes thefollowing measures:

6.1.4.1 Craft Story 21 Recall (Immediate and Delayed)

This is a measure of verbal episodic memory (Craft et al., 1996). Abrief story is read to the participant, who is then asked to retell itimmediately from memory. The primary measure of performance is thenumber of story units recalled. Delayed recall of the story is assessed20 minutes after immediate recall. Other neuropsychological measures areadministered during the delay interval (Range: 0-25 for each recalltrial).

6.1.4.2 Benson Complex Figure Copy & Recall

This test is a simplified form of the Rey-Osterrieth Complex Figure(Possin, Laluz, Alcantar, Miller, & Kramer, 2011). The purpose is toassess visuoconstructional and visual memory functions. In this test,the participant is presented with a figure composed of geometric shapes.The participant is then asked to reproduce (i.e. copy) the figure on thesame page. The accuracy of each shape and its placement are recorded.The primary measure of performance is the total score for copying thefigure (Range: 0-17). Approximately 10-15 minutes after the participantcopies the figure, visual memory is assessed by asking the participantto draw the figure again, from memory, on a blank page. The accuracy ofeach shape and its placement are recorded. The primary measure ofperformance is the total score for the delayed drawing of the Bensonfigure (Range: 0-17).

6.1.4.3 Multilingual Naming Test (MINT)

The MINT is a test of visual confrontation naming (Ivanova, Salmon, &Gollan, 2013). Participants are required to identify (i.e. name) linedrawings of objects. If the initial response is incorrect, semanticand/or phonemic cues are provided, as appropriate. Items are counted ascorrect if spontaneously named after semantic cuing (Range: 0-32).

6.1.4.4 Trail Making Test (Trails A and B)

The Trail Making Test is a test of processing speed and executivefunction. Trails A consists of 25 circles numbered 1 through 25distributed over a white sheet of paper. The participant is instructedto draw a line to connect the circles in ascending numerical order asquickly as possible (150 second maximum). Trails B consists of 25circles containing either numbers (1 through 13) or letters (A throughL) that are randomly distributed across the page, and participants areinstructed to connect the circles in alternating and ascending order(e.g., 1 to A; 2 to B). Performance is judged in terms of time tocomplete each trial. Time to complete Trails B (300 second maximum),adjusted for the time taken to complete Trails A to control forsensorimotor demands of the task, is a sensitive measure of executivefunction and working memory.

6.1.4.5 Verbal Fluency—Category Fluency

Category fluency assesses semantic memory and language fluency in whichparticipants name as many different exemplars of a given semanticcategory as rapidly as possible. Participants will be given 60 secondsto name exemplars in each of two categories: animals and vegetables.

6.1.4.6 Verbal Fluency—Phonemic Fluency

Phonemic Fluency is a measure of word generation that may be sensitiveto dysfunction in the dominant frontal lobe. Participants will be given60 seconds to name exemplars that begin with each of the two letters: Fand L.

6.1.4.7 Number Span Forward and Backward

Number Span assesses two different working memory constructs: ForwardNumber Span measures the capacity for retaining information very brieflyfor the purpose of repeating it exactly, while Backward Number Spanmeasures the ability not only to retain the information but also tomentally manipulate the numbers and recite them in reverse sequence.Numbers for both forward and backward span tests are presented withsequences ranging from 2 to 9 numbers. Two trials are administered ateach sequence length. Two scores are reported for each task: number ofcorrect trials and longest sequence repeated correctly prior to failingtwo consecutive trials of the same length.

6.2 Behavioral and Functional Measures

6.2.1 Clinical Dementia Rating (CDR) Scale—Sum of Boxes (SOB)

The CDR-SOB (Hughes, Berg, Danziger, Coben, & Martin, 1982) is avalidated composite rating of cognition and everyday functioning used inlongitudinal AD research which incorporates both informant input anddirect assessment of performance. It assesses through semi structuredinterview 3 cognitive domains including memory, orientation, andjudgement/problem solving and 3 everyday functional domains includingcommunity affairs, home and hobbies and personal care. There are 5levels of impairment from none CDR=0 to severe CDR=3. The individualdomain scores are added to create a sum of the box scores.

6.2.2 ADCS-Activities of Daily Living (ADL) Scale

The ADCS-ADL scale is a questionnaire developed by the ADCS to assessfunctional performance in participants with AD (Galasko et al., 1997).Scores range from 0 to 75, with higher scores indicating betterfunction.

6.2.3 Neuropsychiatric Inventory (NPI)

The NPI is a well-validated, reliable, multi-item instrument to assesspsychopathology in AD dementia based on the results of an interview withthe study partner (Cummings, 1997). The NPI evaluates both the frequencyand severity of 10 neuropsychiatric features, including delusions,hallucinations, agitation/aggression, dysphoria, anxiety, euphoria,apathy, disinhibition, irritability and lability, and aberrant motorbehavior, as well as evaluates sleep and appetite/eating disorders.Frequency assessments range from 1 (occasionally, less than once perweek) to 4 (very frequently, once or more per day or continuously).Severity assessments range from 1 (mild) to 3 (severe). The score foreach subscale is the product of severity and frequency and the totalscore is the sum of all subscales.

6.3 Modified Hachinski

This brief questionnaire, conducted by a clinician, incorporatesinformation regarding medical history, cognitive symptoms and featuresof stroke, reported by a study partner as well as the neurologicalexamination, and neuroimaging studies (Rosen, Terry, Fuld, Katzman, &Peck, 1980).

6.4 Sheehan Suicidality Tracking Scale (Sheehan STS)

The Sheehan STS (S-STS) is a prospective, patient self-reported orclinician administered rating scale that contains 16 questions to trackboth treatment-emergent suicidal ideation and behaviors (Sheehan, Alphs,et al., 2014; Sheehan, Giddens, & Sheehan, 2014). The S-STS will becompleted on a paper form at the site. At the screening visit, therecall period for completing the S-STS is 12 months prior; at all othervisits, the recall period for completing the S-STS is since the lastvisit. Subjects who have an S-STS score >0 should be evaluated by theinvestigator. If the investigator determines that a subject is at riskof suicide or self-harm, appropriate measures to ensure the subject'ssafety and obtain mental health evaluation must be implemented. Thesubject must immediately be discontinued from the study. The eventshould be recorded as either an AE or SAE as determined by theinvestigator and reported within 24 hours to the Sponsor.

Example 3

Capsules containing 140 mg of troriluzole for use in the studiesdescribed in Example 1 and Example 2 are prepared in the followingproportions.

Composition of Troriluzole Capsules, 140 mg

Component Function Content per Capsule Drug Substance Active 140 mgingredient Mannitol Binder/Filler 60-90 mg MicrocrystallineBinder/Filler 20-40 mg cellulose + dicalcium phosphate¹ MicrocrystallineBinder/Filler 15-40 mg cellulose Hydroxypropyl Binder/Filler  5-10 mgcellulose Crospovidone Disintegrant  5-20 mg Colloidal silicon Glidant0.5-5 mg dioxide Magnesium stearate Lubricant 0.5-5 mg (vegetable grade)

1 Provided as a 75:25 mixture of microcrystalline cellulose andanhydrous dicalcium phosphate.

Example 4

The T2 Protect AD trial has been conducted, which is a Phase 2/3,randomized, double-blind, placebo-controlled study evaluating theefficacy and safety of troriluzole in patients diagnosed withAlzheimer's disease of mild-to-moderate severity (Mini-Mental StateExamination [MMSE] scores of 14-24; mild: 20-24, moderate: 14-19). Thestudy data is summarized in Tables 1 to 6.

Troriluzole exhibited a numerical difference of a potential benefit atWeek 48 on the neuropsychiatric inventory (NPI), an exploratory measure,in participants with mild-to-moderate AD. After 48 weeks, troriluzoletreated participants (n=120) had a LS mean change from baseline of 2.3points on the NPI score, versus 3.8 points for placebo treated (n=125)participants, [difference −1.5, 95% CI: −4.08, 1.10, p-value=0.258].Troriluzole also exhibited numerical differences of a potential benefitat Week 48 on the NPI across subgroups, including analyses consisting ofonly mild AD patients, only moderate AD patients, only ApoE4 positivepatients, and only ApoE4 negative patients. These findings aresuggestive of a potential beneficial effect of troriluzole on reducingthe frequency and severity of neuropsychiatric features inmild-to-moderate AD.

Moreover, a subgroup analysis consisting only of mild AD patientsrevealed that troriluzole exhibited numerical differences of a potentialbenefit at Week 48 on both the ADAS-cog co-primary measure, hippocampalvolumetric MRI secondary measure, and NPI exploratory measure. After 48weeks, troriluzole treated participants with mild AD (n=65) had a LSmean change from baseline of 4.2 points [95% CI: 2.7, 5.7] on theADAS-Cog11 score, versus 4.9 points [95% CI: 3.4, 6.4] for placebotreated (n=63) participants, [difference 0.7, 95% CI: −1.4, 2.7,p-value=0.5233]. After 48 weeks, troriluzole treated participants withmild AD (n=48) had a LS mean percent deformation change from baselinehippocampal volume of −1.1% [95% CI: −1.6, −0.6] versus −1.6% [95% CI:−2.1, −1.0] for placebo treated (n=49) participants [difference −0.5%,95% CI: −1.2, 0.3, p-value=0.2240]. After 48 weeks, troriluzole treatedparticipants with mild AD (n=62) had a LS mean change from baseline of2.1 points on the NPI score, versus 4.2 points for placebo treated(n=63) participants, [difference −2.1, 95% CI: −5.99, 1.78,p-value=0.286]. These findings are suggestive of a potential beneficialand/or disease-modifying effect of troriluzole including improvingcognition, preserving hippocampal brain volumes, and reducingneuropsychiatric features in early stages of AD.

TABLE 1 Co-Primary ADAS-cog 11 at Week 48. Analysis Visit Type StatisticPlacebo Troriluzole Difference¹ ADAS-Cog Total Score Week 48 AnalysisValue N 127 119 Mean (SD) 32.4 (11.93) 31.5 (10.82) Median 30.0 30.0Min, Max    3.0, 64.0    8.0, 66.0 Change from Baseline N 127 119 Mean(SD) 6.1 (8.18) 5.8 (7.40) Median 5.0 6.0 Min, Max −27.0, 43.0 −10.0,37.0 Model Estimates LSMean (SE) 6.7 (0.68) 6.7 (0.70) 0.0 (0.93) DF256.24 95% Cl (5.4, 8.1) (5.3, 8.l) (−1.8, 1.8) P-Value 0.9806

TABLE 2 Co-Primary ADAS-cog 11 at Week 48 (Mild AD Patients Only).Analysis Visit Type Statistic Placebo Troriluzole Difference¹ ADAS-CogTotal Score Week 48 Analysis Value N 63 65 Mean (SD) 26.4 (8.16) 26.2(8.22) Median 26.0 26.0 Min, Max 13.0, 56.0    8.0, 49.0 Change fromBaseline N 63 65 Mean (SD)  5.0 (5.14)  3.9 (5.90) Median 5.0 4.0 Min,Max −5.0, 20.0 −10.0, 24.0 Model Estimates LSMean (SE)  4.9 (0.77)  4.2(0.76) 0.7 (1.02) DF 120.65 95% Cl (3.4, 6.4) (2.7, 5,7) (−1.4, 2.7)

TABLE 3 Co-Primary CDR-SB at Week 48. Analysis Visit Type StatisticPlacebo Troriluzole Difference¹ CDR01-Sum of Boxes Week 48 AnalysisValue N 127 118 Mean (SD) 8.3 (3.05) 8.3 (3.24) Median 8.0 8.0 Min, Max  2.0, 17.0   2.0, 17.0 Change from Baseline N 127 118 Mean (SD) 1.9(2.38) 1.9 (2.37) Median 2.0 2.0 Min, Max −8.0, 8.0  −4.5, 8.5  ModelEstimates LSMean (SE) 1.9 (0.21) 2.1 (0.21) −0.2 (0.28) DF 260.40 95% Cl(1.5, 2.3) (1.7, 2.5) (−0.8. 0.3) P-Value 0.4474

TABLE 4 Co-Primary CDR-SB at Week 48 (Mild AD Patients Only). AnalysisVisit Type Statistic Placebo Troriluzole Difference¹ COR01-Sum of BoxesWeek 48 Analysis Value N 63 62 Mean (SD) 7.1 (2.50) 7.1 (2.79) Median7.0 6.5 Min, Max   2.0, 12.0   2.0, 15.0 Change from Baseline N 63 62Mean (SD) 1.5 (2.48) 1.4 (2.06) Median 1.0 1.0 Min, Max −8.0, 7.5  −4.5,7.0  Model Estimates LSMean (SE) 1.4 (0.30) 1.7 (0.29) −0.3 (0.40) DF138.49 95% Cl (0.8, 1.9) (1.1, 2.2) (−1.1, 0.5) P-Value 0.4347

TABLE 5 Volumetric Hippocampal MRI at Week 48. Analysis Visit TypeStatistic Placebo Troriluzole Difference¹ Hippocampal Volume Change Week48 Analysis Value N 90 87 Mean (SD) −1.1 (1.92) −1.1 (1.50) Median −1.0−0.9 Min, Max −6.4, 3.2 −5.5, 1.9 Model Estimates LSMean (SE) −1.1(0.18) −1.1 (0.18) 0.0 (0.26) DF 174.00 95% Cl (−1.5, −0.8) (−1.4, −0.7)(−0.6, 0.5) P-Value 0.8670

TABLE 6 Volumetric Hippocampal MRI at Week 48 (Mild AD Patients Only).Analysis Visit Type Statistic Placebo Troriluzole Difference¹Hippocampal Volume Change Week 48 Analysis Value N 49 48 Mean (SD) −1.6(2.11) −1.1 (1.61) Median −1.3 −0.9 Min, Max −6.4. 3.2 −5.5. 1.9 ModelEstimates LSMean (SE) −1.6 (0.27) −1.1 (0.27) −0.5 (0.38) DF 94.00 95%Cl (−2.1, −1.0) (−1.6, −0.6) (−1.2, 0.3) P-Value 0.2240

With regard to safety and tolerability, treatment with troriluzole at adose of 280 mg once daily was relatively well tolerated and demonstrateda safety profile consistent with previous studies of troriluzole.

Throughout this application, various publications are referenced byauthor name and date, or by patent number or patent publication number.The disclosures of these publications are hereby incorporated in theirentireties by reference into this application in order to more fullydescribe the state of the art as known to those skilled therein as ofthe date of the invention described and claimed herein. However, thecitation of a reference herein should not be construed as anacknowledgement that such reference is prior art to the presentinvention.

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, numerous equivalents to thespecific procedures described herein. Such equivalents are considered tobe within the scope of this invention and are covered by the followingclaims. For example, it is intended in accordance with the presentinvention that combination therapy using a riluzole prodrug and othertherapeutic agents can be employed to treat ataxia and other associateddiseases. Further, riluzole prodrugs other than those specificallydisclosed in the description and Examples herein can be employed.Furthermore, it is intended that specific items within lists of items,or subset groups of items within larger groups of items, can be combinedwith other specific items, subset groups of items or larger groups ofitems whether or not there is a specific disclosure herein identifyingsuch a combination.

1-17. (canceled)
 18. A method of treating Alzheimer's Disease in apatient in need thereof, the method comprising administering to thepatient a therapeutically effective amount of a riluzole prodrug havingthe following formula:


19. The method of claim 18, wherein the riluzole prodrug is administeredto the patient at a dosage of from about 100 to 400 mg per day.
 20. Themethod of claim 19, wherein the riluzole prodrug is administered to thepatient at a dosage of about 110, or 140, or 150, or 210, or 280, or 350mg per day.
 21. The method of claim 20, wherein the riluzole prodrug isadministered to the patient at a dosage of 280 mg, once per day.
 22. Themethod of claim 20, wherein the riluzole prodrug is administered to thepatient at a dosage of 140 mg, twice per day.
 23. The method of claim18, wherein the riluzole prodrug is administered to the patient once perday.
 24. The method of claim 18, wherein the riluzole prodrug isadministered to the patient twice per day.
 25. The method of claim 18,wherein the riluzole prodrug is administered to the patient in the formof a capsule.
 26. The method of claim 18, wherein the riluzole prodrugis administered to the patient in the form of a tablet.
 27. The methodof claim 18, wherein the riluzole prodrug is administered to the patientfor a duration of from about 8 weeks to 48 weeks.
 28. The method ofclaim 18, wherein the riluzole prodrug is administered to the patientfor a duration of from the onset of treatment to the end of thepatient's life.
 29. A method for improving a response in a patientafflicted with Alzheimer's disease, the method comprising administeringto the patient in need thereof, an effective amount of a riluzoleprodrug having the following formula:


30. The method of claim 29, wherein the improved response is one or moreof overall survival, quality of life, overall response rate, duration ofresponse, delay of onset, or patient reported outcome.
 31. A kit fortreating a patient afflicted with Alzheimer's Disease, the kitcomprising: (a) a riluzole prodrug; and (b) instructions foradministering the riluzole prodrug in the method of claim 18, whereinthe riluzole prodrug has the following formula:


32. A kit for improving a response in a patient afflicted withAlzheimer's Disease, the kit comprising: (a) a riluzole prodrug; and (b)instructions for administering the riluzole prodrug in the method ofclaim 29, wherein the riluzole prodrug has the following formula: